This HTML5 document contains 66 embedded RDF statements represented using HTML+Microdata notation.

The embedded RDF content will be recognized by any processor of HTML5 Microdata.

Namespace Prefixes

PrefixIRI
n2http://linked.opendata.cz/resource/drugbank/drug/
n24http://linked.opendata.cz/resource/drugbank/drug/DB00372/identifier/chemspider/
dctermshttp://purl.org/dc/terms/
foafhttp://xmlns.com/foaf/0.1/
n17http://linked.opendata.cz/resource/mesh/concept/
n11http://linked.opendata.cz/resource/drugbank/company/
n23http://linked.opendata.cz/resource/drugbank/drug/DB00372/identifier/chebi/
n21http://linked.opendata.cz/resource/drugbank/drug/DB00372/identifier/wikipedia/
n22http://linked.opendata.cz/resource/drugbank/drug/DB00372/identifier/pharmgkb/
n15http://bio2rdf.org/drugbank:
n10http://linked.opendata.cz/resource/drugbank/drug/DB00372/identifier/kegg-compound/
admshttp://www.w3.org/ns/adms#
n20http://www.drugs.com/mtm/
n6http://linked.opendata.cz/resource/drugbank/drug/DB00372/identifier/pubchem-compound/
n18http://wifo5-03.informatik.uni-mannheim.de/drugbank/resource/drugs/
n7http://linked.opendata.cz/resource/drugbank/drug/DB00372/identifier/pubchem-substance/
rdfhttp://www.w3.org/1999/02/22-rdf-syntax-ns#
n8http://linked.opendata.cz/resource/drugbank/drug/DB00372/identifier/kegg-drug/
n9http://linked.opendata.cz/resource/drugbank/drug/DB00372/identifier/drugbank/
owlhttp://www.w3.org/2002/07/owl#
n16http://linked.opendata.cz/ontology/mesh/
n3http://linked.opendata.cz/ontology/drugbank/
n13http://www.rxlist.com/cgi/generic2/
n4http://linked.opendata.cz/resource/drugbank/property/
xsdhhttp://www.w3.org/2001/XMLSchema#

Statements

Subject Item
n2:DB00372
rdf:type
n3:Drug
n3:description
A dopamine antagonist that is particularly useful in treating the nausea and vomiting associated with anesthesia, mildly emetic cancer chemotherapy agents, radiation therapy, and toxins. This piperazine phenothiazine does not prevent vertigo or motion sickness. (From AMA Drug Evaluations Annual, 1994, p457)
n3:generalReferences
# Maurer H, Pfleger K: Identification of phenothiazine antihistamines and their metabolites in urine. Arch Toxicol. 1988;62(2-3):185-91. "Pubmed":http://www.ncbi.nlm.nih.gov/pubmed/2904251
n3:group
withdrawn
n3:indication
For the treatment or relief of nausea and vomiting.
n3:manufacturer
n11:271B629C-363D-11E5-9242-09173F13E4C5
owl:sameAs
n15:DB00372 n18:DB00372
dcterms:title
Thiethylperazine
adms:identifier
n6:5440 n7:46506502 n8:D02354 n9:DB00372 n10:C07132 n21:Thiethylperazine n22:PA164748882 n23:9544 n24:5245
n3:mechanismOfAction
Thiethylperazine is an antagonist at types 1, 2, and 4 dopamine receptors, 5-HT receptor types 2A and 2C, muscarinic receptors 1 through 5, alpha(1)-receptors, and histamine H1-receptors. Thiethylperazine's antipsychotic effect is due to antagonism at dopamine and serotonin type 2 receptors, with greater activity at serotonin 5-HT2 receptors than at dopamine type-2 receptors. This may explain the lack of extrapyramidal effects. Thiethylperazine does not appear to block dopamine within the tubero-infundibular tract, explaining the lower incidence of hyperprolactinemia than with typical antipsychotic agents or risperidone. Antagonism at muscarinic receptors, H1-receptors, and alpha(1)-receptors also occurs with thiethylperazine.
n3:packager
n11:271B629B-363D-11E5-9242-09173F13E4C5
n3:routeOfElimination
Thiethylperazine is eliminated in the urine.
n3:synonym
Thiethylperazinum 2-(ethylthio)-10-[3-(4-methylpiperazin-1-yl)propyl]-10H-phenothiazine Thiethylperazin Tietilperazina Thiéthylpérazine Thiethylperazine Norzine
n3:toxicity
Manifestations of acute overdosage of TORECAN (thiethylperazine) can be expected to reflect the CNS effects of the drug and include extrapyramidal symptoms (E.P.S), confusion and convulsions with reduced or absent reflexes, respiratory depression and hypotension.
n3:proteinBinding
60%
n3:salt
n16:hasConcept
n17:M0021336
foaf:page
n13:thiethyl.htm n20:thiethylperazine.html
n3:IUPAC-Name
n4:271B62A1-363D-11E5-9242-09173F13E4C5
n3:InChI
n4:271B62A7-363D-11E5-9242-09173F13E4C5
n3:Molecular-Formula
n4:271B62A6-363D-11E5-9242-09173F13E4C5
n3:Molecular-Weight
n4:271B62A3-363D-11E5-9242-09173F13E4C5
n3:Monoisotopic-Weight
n4:271B62A4-363D-11E5-9242-09173F13E4C5
n3:SMILES
n4:271B62A5-363D-11E5-9242-09173F13E4C5
n3:Water-Solubility
n4:271B62B6-363D-11E5-9242-09173F13E4C5 n4:271B629F-363D-11E5-9242-09173F13E4C5
n3:logP
n4:271B629D-363D-11E5-9242-09173F13E4C5 n4:271B62A0-363D-11E5-9242-09173F13E4C5 n4:271B62B9-363D-11E5-9242-09173F13E4C5
n3:logS
n4:271B629E-363D-11E5-9242-09173F13E4C5
n3:H-Bond-Acceptor-Count
n4:271B62AD-363D-11E5-9242-09173F13E4C5
n3:H-Bond-Donor-Count
n4:271B62AE-363D-11E5-9242-09173F13E4C5
n3:InChIKey
n4:271B62A8-363D-11E5-9242-09173F13E4C5
n3:Polar-Surface-Area--PSA-
n4:271B62A9-363D-11E5-9242-09173F13E4C5
n3:Polarizability
n4:271B62AB-363D-11E5-9242-09173F13E4C5
n3:Refractivity
n4:271B62AA-363D-11E5-9242-09173F13E4C5
n3:Rotatable-Bond-Count
n4:271B62AC-363D-11E5-9242-09173F13E4C5
n3:affectedOrganism
Humans and other mammals
n3:casRegistryNumber
1420-55-9
n3:category
n3:Bioavailability
n4:271B62B2-363D-11E5-9242-09173F13E4C5
n3:Boiling-Point
n4:271B62B8-363D-11E5-9242-09173F13E4C5
n3:Ghose-Filter
n4:271B62B4-363D-11E5-9242-09173F13E4C5
n3:MDDR-Like-Rule
n4:271B62B5-363D-11E5-9242-09173F13E4C5
n3:Melting-Point
n4:271B62B7-363D-11E5-9242-09173F13E4C5
n3:Number-of-Rings
n4:271B62B1-363D-11E5-9242-09173F13E4C5
n3:Physiological-Charge
n4:271B62B0-363D-11E5-9242-09173F13E4C5
n3:Rule-of-Five
n4:271B62B3-363D-11E5-9242-09173F13E4C5
n3:Traditional-IUPAC-Name
n4:271B62A2-363D-11E5-9242-09173F13E4C5
n3:pKa--strongest-basic-
n4:271B62AF-363D-11E5-9242-09173F13E4C5